Vertex Pharmaceuticals is making its biggest-ever acquisition to date, to the tune of $10 billion, of Crinetics Pharmaceuticals. While the deal adds a new potentially blockbuster to Vertex’s pipeline of rare disease drugs, there’s another compound that could have even more promise.
During a conference call, Vertex execs were effusive in their excitement over atumelnant, an investigational treatment for congenital adrenal hyperplasia (CAH), which also has shown potential as a therapy for Cushing syndrome.
The results from a phase 2 trial of the adrenocorticotropic hormone (ACTH) receptor antagonist had Vertex’s leaders fired up.
“That data was eye-opening; we were blown away by it. That’s very, very critical to this field,” said Vertex CEO Reshma Kewalramani on the call.
Duncan McKechnie, the company’s chief commercial officer, commented in the call that it was the “holy grail” in the indication.
The Boston company then fired into the difficult-to-hit brick-and-mortar of Crinetics. At a 102% premium, Vertex is paying $85 per share, just moments before the announcement on Monday at the closing of the marketplace. The deal saw Vertex’s shares fall by 2%.
Palsonify and atumelnant are expected to bring in over $5 billion of potential peak sales annually to the company’s portfolio, says Vertex.
The price premium is “just a bit high,” Myles Minter, of William Blair, wrote in a note to clients, and investors will discuss that, “but we think that’s a fair price to pay if the peak sales number can be achieved.” “Management commentary says that significantly more of the greater than $5 billion peak sales potential lies with the atumelnant opportunity, which has more risk due to its late-stage clinical development.
The companies, which expect the deal to close in the third quarter, match up well. While Vertex is focused on specialty diseases, and its cystic fibrosis (CF) portfolio accounted for 93% of its $12 billion in revenue in 2025, it needs to branch out. Crinetics’ expertise is in endocrine diseases.
This is just the right arrangement for us,” Kewalramani said.
The deal gives Vertex a fifth pillar in its portfolio with endocrine and complementing its existing segment of CF, hematology, pain and renal.
Like its CF offerings, Crinetics’ Vertex will acquire “highly differentiated, best-in-class molecules,” McKechnie added.
One of those is Palsonify, which was approved in September of last year for acromegaly, a disorder which causes excess growth hormone in adults, leading to enlargements of a patient’s face, hands, jaw and feet. The daily oral treatment, which is priced annually at $290,000 in the United States, gives patients a convenience edge to infusions “without sacrificing efficacy,” Leerink Partners said upon Palsonify’s approval.
Successfully integrating two biotechnology companies requires careful coordination across research, manufacturing, regulatory affairs, and commercial operations. Combining scientific expertise and operational resources can accelerate development timelines, improve decision-making, and optimize the use of research investments. A well-planned integration process also helps retain key talent and ensures that ongoing clinical programs continue without significant disruption.
Strengthening the Research Pipeline
Acquisitions of this scale often provide immediate access to multiple clinical and preclinical assets. Instead of building new programs from the ground up, companies can expand their development portfolios through established research platforms and experienced scientific teams. This approach increases the likelihood of delivering innovative therapies while reducing the time required to enter new therapeutic areas.
Vertex has announced its largest acquisition to date, agreeing to acquire endocrine disease specialist Crinetics in a transaction valued at $10 billion.
Future Outlook for Vertex
Following the acquisition, Vertex is expected to continue investing in clinical development, regulatory submissions, and global commercialization of endocrine therapies.
The combined organization may benefit from stronger commercialization capabilities across international markets. Existing global infrastructure, regulatory expertise, and established relationships with healthcare providers can support faster product launches once new therapies receive regulatory approval.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
